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Supratentorial primitive neuroectodermal tumors (sPNET) are rare 
aggressive embryonal tumors of the cerebral hemispheres, which 
predominantly occur in childhood but also arise in adults. Despite 
multi-modal therapy, less than half of affected patients will survive 5 
years post-diagnosis, and late effects associated with current treatment 
protocols are a significant complication in survivors.1 Advances in our 
understanding of the molecular basis of sPNET development will be 
critical to improve outcome. The biological mechanisms underlying 
sPNET pathogenesis, however, remain poorly understood and afford 
few opportunities for the application of novel or targeted therapeutic 
approaches to achieve this objective.
In a recently published systematic screen of 22 glioblastoma tumor 
samples for evidence of genetic mutation in 20,661 protein coding 
genes, the most frequently mutated novel candidate cancer gene was 
IDH1, which encodes cytoplasmic isocitrate dehydrogenase, involved 
in the control of cellular oxidative damage.2 Subsequent mutation 
analysis in an extensive panel identified IDH1 mutations in 12% 
(18/149) of glioblastomas.
A series of studies have now investigated IDH1 mutations in human 
malignancies,2-6 the combined results of which are summarised in 
Table 1. Analysis of central nervous system (CNS) tumors identified 
IDH1 mutations in 37% of cases (590 mutations, 1,603 cases), all 
affecting codon 132. IDH1 mutations appear to occur predominantly 
in neuroepithelial tumors of glial origin. In embryonal brain tumors, no 
evidence of IDH1 mutation has been found in the infratentorial PNET, 
medulloblastoma (0/113), however mutations were identified in a 
third (3/9) of sPNET. In contrast, no IDH1 mutations were detected 
in a panel of 1,053 extracranial tumors. Taken together, these data 
indicate that IDH1 mutations are a common and specific feature 
of glioblastomas and other brain tumors of neuroepithelial and in 
particular glial origin, and suggest a potential role in the pathogenesis 
of sPNET.
We therefore investigated the prevalence of IDH1 mutations in an 
extensive cohort of sPNET, which included 34 primary tumors (mean 
age 9.4 years; range 2 months to 30 years; 8 infant cases <3 years, 
20 childhood cases ≥3 years to 17 years, 6 adult cases ≥18 years). 
Polymerase chain reaction (PCR) was employed to amplify exon 4 of 
IDH1, using previously described primers and methods.5 PCR products 
were subsequently purified (PureLinkTM PCR Purification kit, Invitrogen, 
Paisley, UK) and directly sequenced in forward and reverse directions 
using an Applied Biosystems 3730 DNA Analyser (DBS Genomics, 
Durham University, UK).
Mutations in IDH1 were identified in 2/34 (6%) primary sPNET. 
In both cases, a missense mutation in codon 132 was observed 
(G395A; R132H). Interestingly, both mutations were detected in 
sPNET from adult cases (2/6; ≥18 years at diagnosis), while no muta-
tions were observed in paediatric sPNET (0/28; 0–17 years) (p = 
0.027; Fisher’s exact test). This overall rate of IDH1 mutation in sPNET 
is lower than previously reported (33% (3/9) of cases; Balss et al.5). 
However, detailed examination of the ages at diagnosis of cases in this 
previous study revealed the two datasets are in close agreement; IDH1 
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Table 1  Reported isocitrate dehydrogenase (IDH1) 
mutations in clinically classified human tumor 
biopsies
 Number of Number Mutation Reference 
 tumors of Frequency 
 analyzed mutations (%)
Central nervous system (CNS)
Astrocytic Tumors 917 307 33 2–6
Oligodendroglial Tumors 241 182 76 3–6
Oligoastrocytic Tumors 124 101 81 4–6
Embryonal Tumors 
  sPNET 9 3 33 5 
  Medulloblastoma 113 0 0 5, 6
Ependymal Tumors 87 0 0 4–6
Sellar Region Tumor 23 0 0 5
Cranial & Paraspinal 17 0 0 5 
Nerves Tumors
Meningothelial Cell Tumors 72 0 0 5
Non-CNS
Leukamia 63 0 0 6
Bladder 34 0 0 3
Breast 223 0 0 3, 6
Gastric 57 0 0 6
Colorectal 267 0 0 3, 6
Lung 142 0 0 3, 6
Melanoma 23 0 0 3
Thyroid 42 0 0 3
Ovary 73 0 0 3, 6
Pancreas 118 0 0 3, 6
Prostate 11 0 0 3, 6
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mutations also occurred exclusively in adult sPNET in the study by 
Balss et al.5 (3/6 ≥18 years; 0/3 <18 years) (Prof. A. von Deimling, 
Personal communication). Taken together, these data clearly demon-
strate that mutations in IDH1 are amongst the most frequent mutational 
events identified in sPNET to date, and characterize a significant 
proportion of adult cases (42% (5/12), based on the combined data-
sets), but do not appear to play a major role in paediatric cases (0/31 
in combination; p = 0.0008, Fisher’s exact test).
It is notable that, in studies to date, IDH1 mutations occur specifi-
cally in CNS malignancies and, within these, have only been detected 
in astrocytic, oligodendroglial, oligoastrocytic and adult sPNET, 
suggesting IDH1 plays a role in the development of these tumors, but 
not in other brain tumor types including medulloblastomas. Moreover, 
our findings are consistent with the arguments that (i) PNET arising 
in the infratentorial (i.e., medulloblastoma) and supratentorial (i.e., 
sPNET) compartments display distinct mechanisms of molecular patho-
genesis, despite their histopathological similarities, and (ii) sPNET 
arising in adults and children differ at the molecular level. However, 
whilst the identification of IDH1 mutations in sPNET and other 
neuroepithelial tumors suggests these tumor types may share common 
mechanisms of molecular pathogenesis, it must also be considered that 
the observation of IDH1 mutations in both may reflect the recognized 
challenge that can exist in establishing the histopathological differen-
tial diagnosis of these different supratentorial tumor types.7
In conclusion, these data identify IDH1 mutations as a feature of a 
significant subset of adult sPNET. The significance of IDH1 mutations 
in this group, and any functional contribution they make to tumor 
development is, however, currently unclear. Further studies are now 
required to investigate the role of IDH1 mutations in tumorigenesis, 
their relationship to disease histopathology, and to discover whether 
these findings may be exploited to aid the development of improved 
therapeutic approaches for patients with sPNET.
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